Cancer Discovery

Cancer Discovery

NEWS

RESEARCH WATCH

IN THE SPOTLIGHT

IN FOCUS

REVIEW

Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective Simona Corso and Silvia Giordano

RESEARCH BRIEFS

Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic Transformation Jin Xu et al.

RESEARCH ARTICLES

Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma Thomas Clozel et al. (See In The Spotlight by James J. Steinhardt and Ronald B. Gartenhaus) A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509 James D. Joseph et al. (See In The Spotlight by William G. Nelson and Srinivasan Yegnasubramanian) An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide) Manav Korpal et al. (See In The Spotlight by William G. Nelson and Srinivasan Yegnasubramanian) Systematic Interrogation of 3q26 Identifies TLOC1 and SKIL as Cancer Drivers Daniel Hagerstrand et al. Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer Maria Teresa Herrera-Abreu et al. Unbiased Metabolite Profiling Indicates That a Diminished Thymidine Pool Is the Underlying Mechanism of Colon Cancer Chemoprevention by Alpha-Difluoromethylornithine Mavee Witherspoon et al. (See In The Spotlight by Robert A. Casero Jr)